Glaxo To Cut US Sales Reps For Avandia?
葛兰素可能削减美国的文迪雅销售代表？
Shares of London-based Glaxo fell 57 cents to $39.46 in afternoon trading.
在下午的交易中，伦敦市场上葛兰素史克的股票下跌了57分至39.46美元。
Glaxo had insisted previously on having them sealed in Federal Court.
之前葛兰素在联邦法院坚称这些材料从没有人动过。
Sirtris will remain an autonomous unit within Glaxo, with Dr. Westphal in charge.
SIRTRIS将会作为葛兰素的子公司在韦斯特·法尔博士的管理下保持自主经营。
Glaxo and senior FDA officials said other evidence conflicted with that finding.
葛兰素史克与FDA资深官员则声称另外的证据与此发现相左。
Glaxo based the price of Zantac on an assessment of its value to doctors and patients.
葛兰素是在评估了Zantac对医生和病人的价值后，确定它的价格的。
Millions of diabetics around the world take avandia, glaxo 's second - best - selling drug.
全球数百万的糖尿病患者服用文迪雅，文迪雅是葛兰素史克第二大畅销药物。
For many, including Rebecca Ray, IE manager at Glaxo inc., it is a step in the right direction.
许多人，包括格莱斯公司的工业工程经理瑞贝卡瑞都认为，这是正确方向上的一步。
Glaxo halted the trial "out of an abundance of caution" while it studies the data further, he said.
他还说，格兰素中止临床试验是“出于充分谨慎”，并仍在进一步研究试验数据。
Glaxo assured her that the new viruses. Though drug-resistant, appeared to be relatively benign... She said.
葛兰素安慰她说，新病毒虽然耐药，但似乎没有太大危险。
"We take the allegations that have been raised very seriously," Glaxo said in a statement in response to the accusation.
葛兰素史克在声明中回应相关指控时指出：“我们非常严肃地对待这些指控。”
Glaxo shares rose 5.2 percent in extended U. S. trading to $52 from their close of $49.43 on the New York Stock Exchange.
葛兰素史克股票在美国延长交易时段上涨了5.2%，从纽约证券交易所收盘价$49.43上涨到$52。
Roche referred questions to GlaxoSmithKline. Glaxo representatives did not immediately return calls for comment Monday afternoon.
罗氏将相关问题交由葛兰素处理，而葛兰素史克的发言人在周一下午并没有立即对此发表评论。
Glaxo flier last month promoted a four-year regimen of lamivudine, with favorable statistics superimposed on a Pacific island scene.
上月葛兰素分发了推动4年拉米呋啶方案的小册子，在太平洋岛屿的背景上加上了对自己有利的统计数字。
As it turns out, Glaxo itself had already compiled a similar analysis that also found that the drug raised the risk of heart attacks.
而事实上，该公司自己也已经进行了类似分析，同样发现该药增加心梗的风险。
Glaxo is also awaiting a decision from the European Medicines Agency on the application it filed for Cervarix in Europe in March 2006.
葛兰素公司同时也在等待欧洲药品局的决定，他们于2006年也递交了申请。
Contacted by Dow Jones Newswires, Glaxo didn't comment immediately on the possible impact of this outbreak on production and sales of Relenza.
据道琼斯新闻社联系报道，葛兰素史克公司并没有就此次爆发对瑞乐沙的生产的销售的影响立即做出评价。
Glaxo spokesman said the companies haven't decided what they will do if the FDA rejects the drug again, but Glaxo would own the marketing rights.
一位葛兰素史克发言人表示，如果这次FDA再拒绝申请，两家公司也不知道还能做些什么，但葛兰素史克将拥有洛伐他汀市场开发权这一点是肯定的。
Glaxo spokeswoman Nancy Jo Peparek said there may have been a "breakdown in the process" in the rush to get the abstracts done for the NIH conference.
葛兰素发言人Pekarek说，可能在急于为NIH会议准备摘要的过程中发生了问题。
At London Stock Exchange, the sharp drop in the share price of Glaxo SmithKlein, the largest pharmaceutical company in Europe, has affected the market.
在伦敦股市，欧洲最大的制药企业葛兰素-史克公司的股票价格大幅下跌影响了股市行情。
Spokesmen for Merck and Glaxo say all indications are that their vaccines are safe and effective, and there is no evidence that a booster shot will be needed.
默克和葛兰素的发言人说所有证据表明疫苗是安全有效的。没有证据表明需要再加强注射一针。
In December, Glaxo sought Leungs signature for this years updated research report for the FDA. She read the report and , four days later, fired back a dozen questions.
在十二月，葛兰素要梁为本年度给FDA的最新研究报告签字，她阅读了报告，并在4天后给公司提了许多问题。
Glaxo will pay $720 million in cash, or $22.50 a share, for the company, Sirtris Pharmaceuticals. That is an 84 percent premium to Sirtris’s closing price Tuesday of $12.23.
葛兰素将付出七亿两千万美元的现金或者每股22块五美金的价钱收购这家公司 这个报价比这家公司(SIRTRIS)在星期二$12.23的收盘价多出了84%.
That issue caught the public's attention after it was disclosed that Glaxo had not publicized trials of Paxil in children in which the drug showed little, if any, benefit.
这一问题引起了公众的注意，当Glaxo没有公布Paxil在儿童的实验中显示无效，如果有的话，也相当小的的事情被揭露后。
Mylan had said it received patent licenses and the right to market generic versions of all three dosage strengths of the drug under a 2007 patent lawsuit settlement with Glaxo.
Mylan还表示，目前已经获得出售这些药物的专利执照，有权向市场出售。
Glaxo said Avandia was a valuable option because many patients need multiple drugs to keep blood sugar under control, and a portion of them cannot take some of the other therapies.
葛兰素史克称，文迪雅是一个有价值的选择，因为许多患者需要多样药物控制血糖，他们中的一部分不能采用其它治疗方案。
Glaxo said Avandia was a valuable option because many patients need multiple drugs to keep blood sugar under control, and a portion of them cannot take some of the other therapies.
葛兰素史克称，文迪雅是一个有价值的选择，因为许多患者需要多样药物控制血糖，他们中的一部分不能采用其它治疗方案。
应用推荐